Combination of Antiplatelet and Anticoagulation for AIS Patients Witn Concomitant NVAF and Extracranial/Intracranial Artery Stenosis

• Status: Recruiting
• Trial end date: 2026-01-01
• Target enrollment: 0
• Participant gender: All

Summary

The goal of this clinical trial is to compare the safety and effectiveness of anticoagulation combined with antiplatelet therapy in acute ischemic stroke (AIS) patients with concomitant non-valvular atrial fibrillation (NVAF) and extracranial/intracranial artery stenosis. Participants will be 1:1 randomized into anticoagulation alone or anticoagulation combined with antiplatelet therapy. The primary endpoint is composite events 3 months after enrollment.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University
• Treatments: Anticoagulants

Criteria

Inclusion Criteria:

• Age > 18 years old

• Acute ischemic stroke or TIA with onset < 7 days

• Have a history or newly diagnosed as NVAF

• Concomitant stenosis (>50%) of carotid artery/intracranial artery, of which the ischemic lesion located within the territory

Exclusion Criteria:

• Chronic renal dysfunction (GFR < 30ml/min) or severe hepatic injury

• Have a history or newly diagnosed as valvular heart disease

• Mural thrombus in heart

• Contraindications of anticoagulation or antiplatelet therapy, e.g. severe intracranial hemorrhage

• Myocardial infarction within 6 months before enrollment or received percutaneous coronary intervention in the past

• Have or plan to receive CEA or CAS in the following 3 months

• Life expectancy less than 1 year

• Plan to receive invasive surgery in the following 3 months and have high risk of uncontrollable bleeding

• Pregnant or lactating women

• Individuals identified by researchers as unsuitable for participation in the study due to other reasons.